{
    "root": "2f240285-3f13-4707-e063-6294a90aa221",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Oxcarbazepine",
    "value": "20250227",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00815"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "OXCARBAZEPINE",
            "code": "VZI5B1W380",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7824"
        }
    ],
    "indications": {
        "text": "oxcarbazepine tablets indicated monotherapy adjunctive therapy treatment partial-onset seizures adults monotherapy treatment partial-onset seizures pediatric patients aged 4 years , adjunctive therapy pediatric patients aged 2 years partial-onset seizures .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adults : initiate dose 600 mg/day , given twice day adjunctive therapy : maximum increment 600 mg/day approximately weekly intervals . recommended daily dose 1,200 mg/day ( 2.1 ) conversion monotherapy : withdrawal concomitant 3 6 weeks ; reach maximum dose oxcarbazepine 2 4 weeks increments 600 mg/day weekly intervals recommended daily dose 2,400 mg/day ( 2.2 ) initiation monotherapy : increments 300 mg/day every third day dose 1,200 mg/day ( 2.3 ) initiate one-half usual starting dose increase slowly patients creatinine clearance < 30 ml/min ( 2.7 ) pediatrics : initiation 8 10 mg/kg/day , given twice day . patients aged 2 < 4 years 20 kg , starting dose 16 20 mg/kg/day may considered . recommended daily dose dependent upon patient weight . adjunctive patients ( aged 2 16 years ) : patients aged 4 16 years , target maintenance dose achieved 2 weeks ( 2.4 ) . patients aged 2 < 4 years , maximum maintenance dose achieved 2 4 weeks exceed 60 mg/kg/day ( 2.4 ) conversion monotherapy patients ( aged 4 16 years ) : maximum increment 10 mg/kg/day weekly intervals , concomitant antiepileptic drugs ( aeds ) completely withdrawn 3 6 weeks ( 2.5 ) initiation monotherapy patients ( aged 4 16 years ) : increments 5 mg/kg/day every third day ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "300 mg film-coated tablets : yellow color , capsule-shaped , biconvex , coated tablets scored debossed \u2018 184 \u2019 one side scored side . ndc : 70518-1842-00 ndc : 70518-1842-01 ndc : 70518-1842-02 ndc : 70518-1842-03 ndc : 70518-1842-04 ndc : 70518-1842-05 packaging : 30 1 blister pack packaging : 100 1 box packaging : 1 1 pouch packaging : 100 1 box packaging : 1 1 pouch store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense tight container ( usp ) . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "oxcarbazepine tablets contraindicated patients known hypersensitivity oxcarbazepine components , eslicarbazepine acetate [ ( 5.2 , 5.3 ) ] .",
    "indications_original": "Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.",
    "contraindications_original": "Adults : initiate with a dose of 600 mg/day, given twice a day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1,200 mg/day (2.1) Conversion to Monotherapy: Withdrawal concomitant over 3 to 6 weeks; reach maximum dose of oxcarbazepine in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2,400 mg/day (2.2) Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1,200 mg/day (2.3) Initiate at one-half the usual starting dose and increase slowly in patients with a creatinine clearance <30 mL/min (2.7) Pediatrics: initiation with 8 to 10 mg/kg/day, given twice a day. For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight. Adjunctive Patients (Aged 2 to 16 Years): For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks (2.4). For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not \u00a0exceed 60 mg/kg/day (2.4) Conversion to Monotherapy for Patients (Aged 4 to 16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs (AEDs) can be completely withdrawn over 3 to 6 weeks (2.5) Initiation of Monotherapy for Patients (Aged 4 to 16 Years): Increments of 5 mg/kg/day every third day (2.6)",
    "warningsAndPrecautions_original": "300 mg Film-Coated Tablets:\u00a0\u00a0yellow color, capsule-shaped, biconvex, coated tablets scored and\u00a0\u00a0 debossed with \u2018184\u2019 on one side and scored on other side.\n                  \n                  NDC: 70518-1842-00\n                  NDC: 70518-1842-01\n                  NDC: 70518-1842-02\n                  NDC: 70518-1842-03\n                  NDC: 70518-1842-04\n                  NDC: 70518-1842-05\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 and 30\u00b0C (59\u00b0 and 86\u00b0F) [see USP Controlled Room Temperature].\u00a0Dispense in tight container (USP).\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Oxcarbazepine tablets are contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate\u00a0\u00a0\n \n  [see Warnings and Precautions (\n                     \n                        5.2,\n                     \n                     \n                        5.3\n                     \n                     )].",
    "drug": [
        {
            "name": "Oxcarbazepine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7824"
        }
    ]
}